DK0885215T3 - Nye benzo-1,3-dioxolyl- og benzofuranyl-substituerede pyrrolidinderivater som endthelinantagonister - Google Patents
Nye benzo-1,3-dioxolyl- og benzofuranyl-substituerede pyrrolidinderivater som endthelinantagonisterInfo
- Publication number
- DK0885215T3 DK0885215T3 DK97905816T DK97905816T DK0885215T3 DK 0885215 T3 DK0885215 T3 DK 0885215T3 DK 97905816 T DK97905816 T DK 97905816T DK 97905816 T DK97905816 T DK 97905816T DK 0885215 T3 DK0885215 T3 DK 0885215T3
- Authority
- DK
- Denmark
- Prior art keywords
- endthelin
- dioxolyl
- benzofuranyl
- antagonists
- pyrrolidine derivatives
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- -1 benzofuranyl-substituted pyrrolidine Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60062596A | 1996-02-13 | 1996-02-13 | |
| US79450697A | 1997-02-04 | 1997-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0885215T3 true DK0885215T3 (da) | 2006-08-14 |
Family
ID=27083659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97905816T DK0885215T3 (da) | 1996-02-13 | 1997-02-12 | Nye benzo-1,3-dioxolyl- og benzofuranyl-substituerede pyrrolidinderivater som endthelinantagonister |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP1609790A3 (cs) |
| JP (1) | JP2002504081A (cs) |
| KR (1) | KR100508200B1 (cs) |
| CN (2) | CN1091768C (cs) |
| AR (1) | AR006309A1 (cs) |
| AT (1) | ATE323697T1 (cs) |
| AU (1) | AU2262097A (cs) |
| BR (1) | BR9707509A (cs) |
| CA (2) | CA2634973A1 (cs) |
| CZ (1) | CZ296660B6 (cs) |
| DE (1) | DE69735710T2 (cs) |
| DK (1) | DK0885215T3 (cs) |
| ES (1) | ES2259803T3 (cs) |
| IL (2) | IL125177A0 (cs) |
| NZ (1) | NZ330818A (cs) |
| PT (1) | PT885215E (cs) |
| WO (1) | WO1997030045A1 (cs) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7208517B1 (en) | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| DE19743681A1 (de) * | 1997-10-02 | 1999-04-08 | Knoll Ag | Methode zur Verhinderung der Transplantatabstoßung |
| US6410554B1 (en) | 1998-03-23 | 2002-06-25 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
| WO2000004179A1 (en) * | 1998-07-15 | 2000-01-27 | Bristol-Myers Squibb Company | Stereoselective reductive amination of ketones |
| CA2342217C (en) * | 1998-09-14 | 2009-12-15 | Abbott Laboratories | Process for producing stereoselective nitro compounds |
| TWI306760B (en) * | 2000-08-07 | 2009-03-01 | Abbott Lab | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same |
| WO2002017912A1 (en) * | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| AU2003251739A1 (en) | 2002-07-02 | 2004-01-23 | Schering Corporation | New neuropeptide y y5 receptor antagonists |
| FR2874015B1 (fr) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| CA2904447C (en) | 2007-08-22 | 2017-01-03 | Abbvie Deutschland Gmbh & Co Kg | Therapy for complications of diabetes |
| EP2227466B1 (de) * | 2007-11-30 | 2011-04-20 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte piperidine |
| WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014134201A1 (en) | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| EP2970237B1 (en) | 2013-03-14 | 2017-09-27 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| CN109400567A (zh) * | 2018-12-05 | 2019-03-01 | 华中药业股份有限公司 | 一种合成甘草素的方法 |
| CN113272013A (zh) | 2019-12-17 | 2021-08-17 | 奇努克医疗公司 | 用阿曲生坦治疗IgA肾病的方法 |
| TW202328111A (zh) * | 2021-09-03 | 2023-07-16 | 大陸商深圳信立泰藥業股份有限公司 | 內皮素ａ（ｅｔａ）受體拮抗劑化合物、其藥物組合物及其用途 |
| CN117447453B (zh) * | 2022-07-25 | 2025-09-30 | 深圳信立泰药业股份有限公司 | 一种内皮素a(eta)受体拮抗剂化合物可药用的盐晶型及其制备方法 |
| EP4545520A4 (en) * | 2022-07-25 | 2025-11-26 | Shenzhen Salubris Pharm Co Ltd | Endothelin A receptor antagonist salt (ETA), its preparation process and medical use |
| EP4608396A1 (en) | 2022-10-28 | 2025-09-03 | Chinook Therapeutics, Inc. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993008799A1 (en) * | 1991-11-05 | 1993-05-13 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| AU4679793A (en) * | 1992-07-17 | 1994-02-14 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| EP0776324B1 (en) * | 1994-08-19 | 2002-06-12 | Abbott Laboratories | Endothelin antagonists |
-
1997
- 1997-02-12 CZ CZ0253798A patent/CZ296660B6/cs not_active IP Right Cessation
- 1997-02-12 AU AU22620/97A patent/AU2262097A/en not_active Abandoned
- 1997-02-12 AT AT97905816T patent/ATE323697T1/de not_active IP Right Cessation
- 1997-02-12 WO PCT/US1997/001936 patent/WO1997030045A1/en not_active Ceased
- 1997-02-12 PT PT97905816T patent/PT885215E/pt unknown
- 1997-02-12 EP EP05106190A patent/EP1609790A3/en not_active Withdrawn
- 1997-02-12 DE DE69735710T patent/DE69735710T2/de not_active Expired - Lifetime
- 1997-02-12 EP EP97905816A patent/EP0885215B1/en not_active Expired - Lifetime
- 1997-02-12 CN CN97192184A patent/CN1091768C/zh not_active Expired - Lifetime
- 1997-02-12 ES ES97905816T patent/ES2259803T3/es not_active Expired - Lifetime
- 1997-02-12 CA CA002634973A patent/CA2634973A1/en not_active Abandoned
- 1997-02-12 JP JP52939797A patent/JP2002504081A/ja active Pending
- 1997-02-12 IL IL12517797A patent/IL125177A0/xx active IP Right Grant
- 1997-02-12 CA CA002245587A patent/CA2245587C/en not_active Expired - Fee Related
- 1997-02-12 NZ NZ330818A patent/NZ330818A/xx not_active IP Right Cessation
- 1997-02-12 BR BR9707509A patent/BR9707509A/pt not_active IP Right Cessation
- 1997-02-12 KR KR10-1998-0706247A patent/KR100508200B1/ko not_active Expired - Fee Related
- 1997-02-12 AR ARP970100553A patent/AR006309A1/es unknown
- 1997-02-12 DK DK97905816T patent/DK0885215T3/da active
-
1998
- 1998-07-01 IL IL125177A patent/IL125177A/en not_active IP Right Cessation
-
2002
- 2002-02-09 CN CN02104623A patent/CN1384100A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT885215E (pt) | 2006-08-31 |
| AR006309A1 (es) | 1999-08-25 |
| EP0885215A1 (en) | 1998-12-23 |
| KR100508200B1 (ko) | 2005-12-16 |
| CN1091768C (zh) | 2002-10-02 |
| WO1997030045A1 (en) | 1997-08-21 |
| EP1609790A3 (en) | 2006-01-04 |
| CA2245587C (en) | 2008-12-30 |
| AU2262097A (en) | 1997-09-02 |
| IL125177A0 (en) | 1999-03-12 |
| ES2259803T3 (es) | 2006-10-16 |
| BR9707509A (pt) | 1999-07-27 |
| EP1609790A2 (en) | 2005-12-28 |
| NZ330818A (en) | 2000-05-26 |
| CN1384100A (zh) | 2002-12-11 |
| DE69735710T2 (de) | 2007-03-29 |
| JP2002504081A (ja) | 2002-02-05 |
| ATE323697T1 (de) | 2006-05-15 |
| CA2245587A1 (en) | 1997-08-21 |
| DE69735710D1 (de) | 2006-05-24 |
| CN1219172A (zh) | 1999-06-09 |
| CA2634973A1 (en) | 1997-08-21 |
| KR19990082514A (ko) | 1999-11-25 |
| IL125177A (en) | 2007-12-03 |
| CZ296660B6 (cs) | 2006-05-17 |
| EP0885215B1 (en) | 2006-04-19 |
| CZ253798A3 (cs) | 1999-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0885215T3 (da) | Nye benzo-1,3-dioxolyl- og benzofuranyl-substituerede pyrrolidinderivater som endthelinantagonister | |
| NO983356L (no) | Nye 19-nor-pregnenderivater | |
| ATE226212T1 (de) | 2-(purin-9-)-tetrahydrofuran-3,4-diol-derivate | |
| DK0946512T3 (da) | 6-Phenylpyridyl-2-aminderivater, der er nyttige som NOS-inhibitorer | |
| NO970511D0 (no) | Nye substituerte oksazolidinoner | |
| DE69736711D1 (de) | Substituierte 6,5-heterobicyclische-derivate | |
| DK0925298T3 (da) | Substituerede 6,6-heterobicykliske derivater | |
| NO992400D0 (no) | Nye substituerte pyrazolderivater | |
| NO20001938D0 (no) | Nye aryloksy-alkyl-dialkylaminer | |
| NO985671L (no) | Nye Tiazolidindion-2-derivater som er 4-diketonsubstituerte, fremgangsmÕte | |
| NO996115L (no) | Azetidinylpropylpiperidin-derivater, intermediater og anvendelse som tachykinin-antagonister | |
| ATE231847T1 (de) | Substituierte 1,2,3,4- tetrahydronaphthalinderivate | |
| DK1237857T3 (da) | Nye Phenalkyloxyphenylderivater | |
| DK0871623T3 (da) | 3-Azetinidylalkylpiperidiner eller -pyrrolidiner som tachykininantagonister | |
| DK0922050T3 (da) | 3-Descladinose-2,3-anhydroerythromycin-derivater | |
| DK0964863T3 (da) | Oxazolidinoner som 5-HT2A-antagonister | |
| NO960268D0 (no) | Nye dialkoksypyridinylbenzimidazolderivater | |
| NO961333D0 (no) | Nye pyrazolderivater som angiotensin-II-antagonister | |
| NO992066D0 (no) | Piperazinoderivater som neurokininantagonister | |
| NO20005857L (no) | Nye blandinger | |
| DK0931087T3 (da) | Nye pyranosidderivater | |
| NO950684L (no) | Nye imidazopyridinderivater som angiotensin II-antagonister | |
| NO20005681D0 (no) | Nye formuleringer som inneholder paroxetin | |
| NO20002575D0 (no) | Substituerte oksimer som neurokininantagonister | |
| NO983656D0 (no) | Heterocyklyl-ergolinderivater som 5-HT1A reseptorligander |